| HOME >> MEDICINE >> TECHNOLOGY |
Mission Health System Commences Production of RIVA-produced IV
Solution 33
Mission Health Systems Selects Automation Solution from HIS 34
Applied Research Associates Bags Contract for Packaged
Intravenous Fluids 34
Bivigam™ Dossier Submitted to US FDA by Biotest 34
Grifols Bags EMA License for Marketing Flebogamma® DIF 100mg/ml 34
Hospira Announces Migration to Non-DEHP Based IV
Administration Units 35
Grifols and Health Robotics Ink Collaboration Agreement 35
Marck Biosciences Obtains Approval for Low Volume Parenteral
Plant 35
Grifols Receives Approval for Sterile Albumin Filling Unit 36
Grifols Establishes New Production Unit 36
Fresenius Medical to Form JV with Galenica 36
B. Braun Inks Agreement with Health Robotics 36
Fresenius Medical Care Closes Agreement with Luitpold
Pharmaceuticals 36
Grifols Receives Approval for Intravenous Immunoglobulin
Flebogamma® DIF 37
8. FOCUS ON SELECT PLAYERS 38
B. Braun Melsungen AG (Germany) 38
Baxter International, Inc. (US) 38
Baxter India Private Limited (India) 39
Claris Lifesciences Ltd. (India) 39
Fresenius SE & Co. KGaA (Germany) 39
Fresenius Kabi AG (Germany) 40
Galenica Ltd. (Switzerland) 40
Grifols S.A. (Spain) 40
Hospira, Inc. (US) 41
Sichuan Kelun Pharmaceutical Co., Ltd. 41
Liqvor Pharmaceuticals (Armenia) 42
Marck Biosciences Ltd. (India) 42
Otsuka Pharmaceutical Co. Ltd. (Japan) 42
Pfizer, Inc. (US) 43
Sino-Swed Pharmaceutical (China) 43
Terumo Corporation (Japan) 43
Watson Pharmaceuticals, Inc. (US) 44
9. GLOBAL MARKET PERSPECTIVE 45
Table 2: World Recent Past, Current and Future Analysis for
Intravenous Solutions by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific, Latin America, and Rest
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |